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Abstract
Recurrence of membranous nephropathy (MN) is fre-
quently seen after transplantation. However, there are no
published data about the course of MN in the native
kidneys after transplantation. Disease progression in almost
all cases is assumed to be the ‘natural’ course after trans-
plantation. We report on a patient suffering from end-stage
renal disease due to MN. Eight years after transplantation,
nephrectomy was performed due to chronic rejection and
unexpectedly, partial recovery of native kidney function
was noted. As far as we know, there is no other similar
case reported in the literature. The potential impact of the
immunosuppression, especially of calcineurin inhibitors, is
discussed.
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Background
Of all patients who receive a kidney transplant, 20–40%
have glomerulonephritis as the cause of renal failure [1]. In
patients with membranous nephropathy (MN), a recurrence
rate of 30% is reported [2]. The management of recurrent
MN is based on anecdotal reports and extrapolation of data
on the management of native kidney MN. Spontaneous re-
missions, responses to, and failures with immunosuppres-
sive treatment have all been reported. However, there are
no published data about the course of MN in native kid-
neys after transplantation suggesting that further disease
progression is the ‘natural’ course after transplantation.
We report on a patient suffering from end-stage renal dis-
ease due to MN with unexpected recovery of native kidney
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Fig. 1. Time course of membranous nephropathy in native kidneys and
in a kidney graft (shown until graft nephrectomy). Serum creatinine (red
line, µmol/l) and proteinuria [urine protein/urine creatinine (grey area,
mg/mmol)] over time (years) before and after transplantation. P: pred-
nisone; CP: cyclophosphamide; CyA: cyclosporine A neoral; CHOP: cy-
clophosphamide, doxorubicin, vincristine and dexamethasone; Rit: ritux-
imab; MMF: mycophenolate mofetil; Bx: biopsy.
function and discuss the possible impact of immunosup-
pression (IS) on the outcome.
Case Report
In a nine-year-old girl suffering from a nephrotic syndrome,
a kidney biopsy revealed MN stages (II) to III with prolifer-
ative crescents (Figures 1 and 2, Table 1). Secondary causes
of MN such as a history of nonsteroidal anti-inflammatory
agent usage, hepatitis B and C, other infections or a malig-
nant tumour were ruled out.
In spite of therapy with prednisone and two courses of
cyclophosphamide (2 mg/kg/day), proteinuria persisted and
kidney function worsened steadily. Within 5 years, the kid-
neys failed [serum creatinine 7.9 mg/dl, estimated glomeru-
lar filtration rate (eGFR) by MDRD 8 ml/min/1.73 m2] [4]
and deceased-donor kidney transplantation was performed.
The IS consisted of cyclosporine, azathioprine and pred-
nisone. A graft biopsy at month 4 detected early recur-
rence of MN by immunofluorescence and interstitial rejec-
tion (Banff IA), which was treated by methylprednisolone
(Figure 1, Table 1) [3]. A further graft biopsy at month 9
again revealed interstitial rejection (Banff IA) treated by
methylprednisolone and by switching cyclosporine A to
tacrolimus (Figure 1, Table 1) [3]. Thereafter, graft func-
tion remained stable (serum creatinine 1.6 mg/dl, eGFR by
MDRD 39 ml/min/1.73 m2) [4]. Six years later, a diffuse
large B-cell lymphoma of the small bowel was diagnosed.
Segmental resection was performed, and full remission was
achieved after eight cycles of CHOP (cyclophosphamide,
doxorubicin, vincristine and dexamethasone) in combina-
tion with eight doses of rituximab (375 mg/m2). IS was
stopped, and within 1 month proteinuria rose heavily from
0.15 to 2 g/day. A graft biopsy confirmed recurrence of
MN without any signs of interstitial or vascular rejection T
ab
le
1.
O
ve
rv
ie
w
of
th
e
m
or
ph
ol
og
ic
al
fi
nd
in
gs
in
na
tiv
e
bi
op
si
es
an
d
in
th
e
re
na
lt
ra
ns
pl
an
t
B
io
ps
ie
s
Fi
rs
tn
at
iv
e
ki
dn
ey
Z
er
o
ho
ur
Fi
rs
tT
x
S
ec
on
d
T
x
T
hi
rd
T
x
T
x–
N
x
S
ec
on
d
na
tiv
e
ki
dn
ey
T
im
e
be
fo
re
an
d
af
te
r
T
x
Y
ea
r-
3
D
ay
0
M
on
th
4
M
on
th
9
Y
ea
r
7
Y
ea
r
8
Y
ea
r
10
N
o
gl
om
er
ul
if
or
L
M
14
/2
ob
so
le
sc
en
t
3/
0
16
/0
20
/0
29
/1
2
ob
so
le
sc
en
t
23
/1
2
ob
so
le
sc
en
t
D
ia
gn
os
is
M
N
w
it
h
cr
es
ce
nt
s
in
3/
12
gl
om
er
ul
i
N
or
m
al
M
N
+
re
je
ct
io
n
R
ej
ec
ti
on
a
M
N
E
nd
-s
ta
ge
co
nt
ra
ct
ed
ki
dn
ey
w
it
h
va
sc
ul
ar
re
je
ct
io
n
M
N
w
it
h
cr
es
ce
nt
s
an
d
fi
br
in
in
3/
11
gl
om
er
ul
i
In
te
rs
ti
ti
al
fi
br
os
is
10
0%
0%
30
%
50
%
60
%
70
%
Tu
bu
la
r
at
ro
ph
y
50
%
0%
20
%
60
%
60
%
70
%
In
fl
am
m
at
io
n
S
li
gh
t
A
bs
en
t
B
an
ff
IA
B
an
ff
IA
M
as
si
ve
fo
ca
li
n
sc
ar
s
M
ed
iu
m
A
rt
er
io
la
r
hy
al
in
os
is
N
o
N
o
M
in
im
al
M
in
im
al
M
in
im
al
S
ev
er
e
(p
ar
tly
:C
N
I
ty
pe
)
IF
/I
H
C
pe
ri
ph
er
al
de
po
si
ts
Ig
G
,C
3
ve
ry
w
ea
k
N
o
Ig
G
,I
gM
,
Ig
A
po
si
tiv
e
C
3
ne
ga
tiv
e
IH
C
a
in
pa
ra
ff
in
:
C
5b
-9
m
in
im
al
Ig
G
,I
gM
,I
gA
,C
3,
C
4,
C
5b
-9
nd
Ig
G
,I
gM
,I
gA
,C
1q
,C
3,
C
4,
C
5b
-9
an
d
fi
br
in
og
en
E
le
ct
ro
n
m
ic
ro
sc
op
y
M
N
st
ag
es
II
an
d
II
I
nd
nd
nd
nd
nd
M
N
st
ag
es
II
an
d
II
I
T
x:
tr
an
sp
la
nt
,
N
x:
ne
ph
re
ct
om
y,
N
o:
nu
m
be
r,
L
M
:
li
gh
t
m
ic
ro
sc
op
y,
M
N
:
m
em
br
an
ou
s
ne
ph
ro
pa
th
y,
IF
:
im
m
un
of
lu
or
es
ce
nc
e,
IH
C
:
im
m
un
oh
is
to
ch
em
is
tr
y,
nd
:
no
t
do
ne
,
C
N
I:
ca
lc
in
eu
ri
n
in
hi
bi
to
r,
Ig
:
im
m
un
og
lo
bu
li
n,
C
:c
om
pl
em
en
t.
a I
n
th
e
se
co
nd
bi
op
sy
,M
N
co
ul
d
no
tb
e
di
ag
no
se
d
by
th
e
us
e
of
pa
ra
ff
in
fo
r
IH
C
.
Recovery of native kidney function 1347
Fig. 2. First native kidney biopsy performed 3 years before transplantation: (A) glomerulus with thickened basement membranes embedded in a
tubulo-interstitial space showing tubular atrophy, fibrosis and scattered inflammatory infiltrates (PAS, ×200); (B) peripheral capillary loops with
subepithelial deposits partly separated by spike or surrounded by newly formed basement membrane (EM, ×3300).
(Figures 1 and 3, Table 1). Four months after chemother-
apy, mycophenolate was added to prednisone. During the
next 2 years, serum creatinine increased slightly and kid-
ney graft hydronephrosis due to ureter stenosis was diag-
nosed and treated by ureter catheter insertion. Five months
later, the patient suffered from pain in the graft region and,
surprisingly, Doppler ultrasound showed no perfusion of
the graft. The immediate surgical exploration revealed a
blue graft without perfusion. Misled by only a slight in-
crease in serum creatinine (1.9 mg/dl, eGFR by MDRD
34 ml/min/1.73 m2) [4], graft nephrectomy was not per-
Fig. 3. Third graft biopsy performed 7 years after transplantation: (A)
overview of the biopsy with severe scarring, glomerular obsolescence and
collapse, and one hypertrophic glomerulus surrounded by hypertrophic
tubules (PAS, ×40); (B) collapsed glomerulus with granular IgG deposits
in the loop periphery (immunofluorescence, ×250).
formed despite the disastrous finding. Severe acute re-
jection was assumed and treated with methylprednisolone.
Three days later, serum creatinine remained unchanged but
magnetic resonance angiography confirmed the absence of
any perfusion. However, as a surprising additional find-
ing, both native kidneys showed contrast agent elimination
(Figure 4). Graft nephrectomy was performed, serum cre-
atinine actually remained stable and proteinuria was un-
changed. Histologically, end-stage vascular rejection of the
kidney and ureter was seen (Figure 1, Table 1). Over the
next 2 years, proteinuria increased and kidney function
worsened. Therefore, 13 years after the first biopsy a sec-
ond biopsy of the native kidneys was performed (serum
creatinine 4.7 mg/dl, eGFR by MDRD 9 ml/min/1.73 m2)
[3] and revealed MN very similar to the first biopsy
(Figure 5, Table 1). Twelve days later, dialysis had to be
started. The patient died unexpectedly 2 months later due
to central venous embolism.
Discussion
To our knowledge, we report on the first case of recovery of
native kidney function after kidney transplantation in a pa-
tient suffering from ESRD due to MN. The course of MN
was uncommon, due to the young age of the patient, the
rapid progression of the disease and the presence of cres-
cents in the first biopsy. However, if and to what extent the
peculiar characteristics of the native disease contributed to
the unusual course remains unclear. Treatment recommen-
dations depend on the risk for progression that depends on
renal function and proteinuria. Unfortunately, for high-risk
patients there are limited data concerning different therapy
modalities as for our patient [5]. Our patient received two
courses of cyclophoshamide and steroids, obviously with-
out a benefit.
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Fig. 4. MR Angiography Abdomen before graft nephrectomy: Kidney
graft and vessels in the right fossa iliaca not visible due to the absence of
perfusion (cartoon in orange shows place of graft). Contrast elimination
of both native kidneys.
After transplantation, we are not able to assess exactly
when and to what extent the native kidneys started to con-
tribute to the ‘global’ kidney function. Cattran et al. showed
that cyclosporine may be effective in reducing both the rate
of renal deterioration and proteinuria in patients with MN
[6]. Praga et al. reported on a reduction in the risk for
deteriorating renal function and greater decrease in pro-
teinuria in patients with MN treated with tacrolimus [7]. In
our patient after stopping tacrolimus, a marked increase
of proteinuria was seen indicating that tacrolimus (and
previously cyclosporine) could have contributed to the
remission of MN in the native kidneys. The assumption
that proteinuria originated from the native kidneys is based
on similar histologies in graft biopsies and on persisting
proteinuria after graft nephrectomy. However, an increase
of proteinuria after calcineurin inhibitor (CNI) interrup-
tion is relatively common not only in MN but also in
other proteinuric nephropathies. The reduction of protein-
uria does not invariably mean that therapy is effective in
improving the disease and that its interruption is associated
with a recurrence of glomerular injury. Changes in uri-
nary protein excretion may simply rely on the vasoconstric-
tive effect of CNI on renal blood flow. After treatment for
posttransplant lymphoproliferative disease (PTLD), CNI
was not reintroduced because of the risk of relapse of
PTLD. This could explain why the native kidneys failed
thereafter.
Fig. 5. Second native kidney biopsy performed 2 years after graft nephrec-
tomy: (A) two hypertrophic glomeruli with thickened basement mem-
branes and slightly increased mesangial matrix. Note: arteriolopathy of the
CNI type (PAS, ×200); (B) glomerulus with granular peripheral deposits
for IgA. Identical deposits were seen for other antigens and complement
factors (immunofluorescence, ×250); (C) thickened peripheral glomeru-
lar capillary loops with subepithelial deposits separated by spikes (EM,
×2200).
In contrast to a possible effect of CNIs on MN in the
native kidneys, CNIs could not prevent recurrence of MN
in our patient’s graft. Schwarz et al. found, in a retrospective
analysis, that the occurrence of de novo MN could not be
prevented by cyclosporine and was not resolved by further
steroid medication [8]. However, it is probably not valid
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to transfer the situation of de novo MN to recurrent MN.
Therefore, currently we do not know if CNI-based IS is
beneficial in MN after transplantation.
In published studies, rituximab in idiopathic MN has a
significant effect on reduction of proteinuria [9,10]. The oc-
currence of proteinuria during rituximab therapy for PTLD
implicates that the B-cell depleting therapy had no positive
effect on the further course of our patient’s MN.
It remains controversial how and when to restart im-
munosuppressive therapy after PTLD [11]. Generally, we
stop maintenance IS as long as a patient is treated by
chemotherapy and restart carefully with low doses of my-
cophenolate or sirolimus in combination with prednisone.
In spite of this approach, our patient lost her graft by vas-
cular rejection. Misled by a nearly stable serum creatinine,
the rejection remained unrecognized until the patient had
symptoms. A hint could have been hydronephrosis of the
graft: stenosis of the ureter was caused by vascular rejection
as seen histologically [12].
Certainly, our case of recurrence of native kidney func-
tion 8 years after kidney transplantation in a patient suf-
fering from MN is an extreme rarity. The impact of CNIs
in this unusual course of MN after transplantation remains
unclear. The role of newer therapy regimens, such as anti-
CD20 antibodies, on MN has to be further studied.
Conflict of interest statements. None declared.
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